Global Cancer Biological Therapy Market 2018 Size, Development Status, Type and Application, Segmentation, Forecast by 2023

WiseGuyReports.com adds “Cancer Biological Therapy Market 2018 Global Analysis, Growth, Trends and Opportunities Research Report Forecasting to 2023”reports to its database.

Pune, India - January 12, 2018 /MarketersMedia/ —

Cancer Biological Therapy Market:

Executive Summary

Biological therapy treatment is done with the help of living organisms, parts of living organisms or laboratory manufactured version of such content. There are various types of biological therapies, which inhibit specific molecules involved in development and growth of cancer tumor. Such therapies known as; cancer targeted therapies.

The global cancer biological therapy market is expected to reach USD 82,276.8 million by 2023 at a CAGR of 4.7% during the forecasted period.  

The global cancer biological therapy market is segmented on the basis of phases, types, end users and regions. On the basis of phases, the market is segmented into phase I, phase II and phase III. In stage I & II the real impact of these therapies is seen and giving a success rate of 35% in Phase 1 and 20% in Phase II. The success rate of phase I is 35%.

On the basis on types, the global cancer biological therapy market is segmented into monoclonal antibodies, cancer growth blockers, interferons, interleukins, gene therapy, targeted drug delivery, colony stimulating factor, cancer vaccines and others. Monoclonal antibodies accounted for the largest market share of the global cancer biological therapy market. Colony stimulating factor is the fastest growing market at a CAGR of 5.2% during the forecasted period.

On the basis on end users, hospitals & clinics dominates the global cancer biological therapy market. Registering USD 26,790.6 million in 2016 and expected to reach at USD 38,471.9 million by 2023 at the rate of 4.4 % from 2016-2023. 

On the basis of regions, the market is segmented into North America, Europe, Asia-Pacific and the Middle East & Africa. North America has the dominating market for cancer biological therapy. The cancer biological therapy market for North America is estimated at USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%.

Request Sample Report @ https://www.wiseguyreports.com/sample-request/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Players

The leading market players in the global cancer biological therapy market include Merck Inc., F. Hoffmann-La Roche Ltd, Novartis AG, Amgen Inc., Bristol-Myers Squibb, Celgene, ELI Lilly and Company, EnGeneIC, and Pfizer

Study objectives

To provide detailed analysis of the market structure along with forecast of the various segments and sub-segments of the global cancer biological therapy market
To provide insights about factors influencing and affecting the market growth
To provide historical and forecast revenue of the market segments and sub-segments with respect to countries
To provide historical and forecast revenue of the market segments based on channels, applications, and regions for the global cancer biological therapy market.
To provide strategic profiling of key players in the market, and comprehensively analysing their market share, core competencies, and drawing a competitive landscape for the market
To provide economical factors that influences the global cancer biological therapy market
To provide detailed analysis of the value chain and supply chain of the global cancer biological therapy market

Target Audience

Pharmaceutical Companies
Pharmaceutical Suppliers
Cancer Research Organizations
Potential Investors
Key Executive (CEO and COO) and Strategy Growth Manager
Reaserch Companies

For further information on this report, visit - https://www.wiseguyreports.com/enquiry/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Key Findings

North America accounted for the largest market share in the global cancer biological therapy market, USD 19,481.2 million in 2016 and expected to reach by USD 29,516.9 million by 2023 at a fastest CAGR of 5.10%
Colony stimulating factor is the fastest growing segment with a CAGR of and 5.2% in the global cancer biological therapy market, by types
Hospitals and clinics is contributing remarkable share in the market registering 47.8% in the global cancer biological therapy market, by end users in 2016

The reports also covers regional analysis

North America
o US

o Canada

Europe
o Germany

o France

o U.K.

o Italy

o Spain

o Rest of Europe

Asia Pacific
o Japan

o China

o India

o Republic of Korea

o Rest of Asia-Pacific

Middle East & Africa
o Middle East

o Africa

Continuous…

Buy this Report @ https://www.wiseguyreports.com/checkout?currency=one_user-USD&report_id=1793685

Contact Info:
Name: NORAH TRENT
Email: Send Email
Organization: Wise Guy Research Consultants Pvt Ltd
Address: Office No. 528, Amanora Chambers Pune - 411028 Maharashtra, India
Phone: +1-646-845-9349 (US); +44 208 133 9349 (UK)

Source URL: https://marketersmedia.com/global-cancer-biological-therapy-market-2018-size-development-status-type-and-application-segmentation-forecast-by-2023/286775

For more information, please visit https://www.wiseguyreports.com/reports/1793685-global-cancer-biological-therapy-analysis-forecast-2016-to-2023

Source: MarketersMedia

Release ID: 286775

Latest News

Forests group halts plan to endorse Indonesian paper giant

Aug 20, 2018

JAKARTA, Indonesia — The main global group for certifying sustainable wood has suspended plans to give its influential endorsement to Indonesian paper giant Sinarmas after revelations it cut down tropical forests and used an opaque corporate structure to hide its activities. The Forest Stewardship Council said Thursday that it had halted a process that could have enabled the Asia Pulp & Paper arm of Sinarmas to be readmitted to the organization. The group said it is awaiting information from the conglomerate "related to its corporate structure and alleged unacceptable forest management activities" by companies thought related to it and wants...

New Malaysian government repeals law banning 'fake news'

Aug 20, 2018

KUALA LUMPUR, Malaysia — Malaysia's new government on Thursday repealed a widely criticized law prohibiting "fake news," in a move hailed as a landmark moment for human rights by a group of Southeast Asian lawmakers. The bill was rushed through Parliament in April under former Prime Minister Najib Razak despite concerns that it would be used to silence dissent ahead of a May 9 general election. It carried a penalty of up to six years in jail and a fine of 500,000 ringgit ($128,000). Najib's long-ruling coalition was ousted in the polls, ushering in the country's first transition of power...

Malaysia PM on China, Rohingya, Singapore, graft and sea row

Aug 20, 2018

PUTRAJAYA, Malaysia — Malaysian Prime Minister Mahathir Mohamad commented on lopsided China-backed projects, treatment of Myanmar's Rohingya Muslims, the South China Sea furor, a water treaty with Singapore and the country's financial mess in an interview Monday with The Associated Press. Here are excerpts: ___ AX CHINA-BACKED PROJECTS Days before heading to Beijing for his first visit since his stunning electoral victory three months ago, Mahathir said Malaysia doesn't need a Chinese-backed $20 billion East Coast Rail Link and two energy pipelines worth $2.3 billion. The projects have been suspended pending renegotiation. "We don't think they are viable. So if...

Malaysia eyes more than 10-fold hike in Singapore water deal

Aug 20, 2018

PUTRAJAYA, Malaysia — Malaysia's prime minister said Monday he is seeking to hike the price of water sold to neighboring Singapore by more than 10 times as his country searches for ways to pay off massive debts. Prime Minister Mahathir Mohamad, who shot back to power in an electoral upset in May, told The Associated Press that a decades-old treaty governing the water agreement needs to be revised to reflect increases in the cost of living. The water deal has long been a point of contention between the two countries. Mahathir said in June he wants to renegotiate the deal....

AP Interview: Malaysia's Mahathir aims to scrap China deals

Aug 20, 2018

PUTRAJAYA, Malaysia — Malaysia is looking to cancel multibillion-dollar Chinese-backed infrastructure projects signed by the previous scandal-tainted government as it digs itself out of debt, Malaysia's prime minister said Monday during an extensive interview in which he also blasted Myanmar's treatment of Rohingya Muslims as "grossly unjust." Mahathir Mohamad, at 93 the world's oldest prime minister, spoke with The Associated Press days before he heads to Beijing for his first visit since returning to power in a stunning electoral upset three months ago. Mahathir said he wants to maintain good relations with China and welcomes its investment, so long as...

Penggerak pasaran mengikut TradingView

About Us

Duniaga is Malaysia’s top local source for business news and information where people head to stay connected with the business news. We give daily in-depth analysis on the business happenings in the country.

Contact us: sales[at]duniaga.com

Subscribe Now!